“President Trump issued four orders on prescription drug pricing today — four chances to truly do something revolutionary — and yet did not deliver what seniors and their advocates have been demanding: allowing the Medicare program to negotiate prices directly with drug-makers. The Congressional Budget Office estimated that direct negotiation would lower Medicare’s drug costs by $345 billion over six years. But President Trump opposes House legislation (H.R. 3) that would give Medicare negotiation authority, just like the Veterans Administration already has. Seniors suffering from soaring prescription prices will not be fooled by grandiose pronouncements at a press conference that appear to be a ‘Hail Mary’ pass during an election year. Any proposal that doesn’t include Medicare price negotiation can’t be taken seriously, because any serious policy effort must include it to address the underlying problem of price gouging.” – Max Richtman, president and CEO of the National Committee to Preserve Social Security and Medicare
The National Committee, a nonprofit, nonpartisan organization acts in the interests of its membership through advocacy, education, services, grassroots efforts and the leadership of the Board of Directors and professional staff. The work of the National Committee is directed toward developing better-informed citizens and voters.
Media Inquiries to:
Pamela Causey 202-216-8378; 202-236-2123
Walter Gottlieb 202-216-8414